CVS Health Corporation $CVS Shares Sold by Johnson Investment Counsel Inc.

Johnson Investment Counsel Inc. lessened its holdings in CVS Health Corporation (NYSE:CVS) by 5.0% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 22,391 shares of the pharmacy operator’s stock after selling 1,180 shares during the quarter. Johnson Investment Counsel Inc.’s holdings in CVS Health were worth $1,545,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of the stock. Essex Financial Services Inc. boosted its position in CVS Health by 0.8% in the 1st quarter. Essex Financial Services Inc. now owns 20,705 shares of the pharmacy operator’s stock worth $1,403,000 after purchasing an additional 166 shares in the last quarter. Williams Financial LLC boosted its position in CVS Health by 2.5% in the 2nd quarter. Williams Financial LLC now owns 6,923 shares of the pharmacy operator’s stock worth $478,000 after purchasing an additional 167 shares in the last quarter. Hemington Wealth Management boosted its position in CVS Health by 33.7% in the 1st quarter. Hemington Wealth Management now owns 682 shares of the pharmacy operator’s stock worth $46,000 after purchasing an additional 172 shares in the last quarter. Sumitomo Life Insurance Co. lifted its position in shares of CVS Health by 1.0% during the 1st quarter. Sumitomo Life Insurance Co. now owns 17,114 shares of the pharmacy operator’s stock valued at $1,159,000 after buying an additional 174 shares in the last quarter. Finally, Koshinski Asset Management Inc. lifted its position in shares of CVS Health by 3.7% during the 1st quarter. Koshinski Asset Management Inc. now owns 4,930 shares of the pharmacy operator’s stock valued at $334,000 after buying an additional 178 shares in the last quarter. Hedge funds and other institutional investors own 80.66% of the company’s stock.

CVS Health Stock Up 0.8%

CVS opened at $78.50 on Tuesday. The business’s fifty day moving average is $72.63 and its two-hundred day moving average is $67.75. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.62 and a current ratio of 0.80. The company has a market cap of $99.56 billion, a price-to-earnings ratio of 21.93, a PEG ratio of 0.86 and a beta of 0.60. CVS Health Corporation has a one year low of $43.56 and a one year high of $79.68.

CVS Health (NYSE:CVS) last posted its earnings results on Thursday, July 31st. The pharmacy operator reported $1.81 EPS for the quarter, topping analysts’ consensus estimates of $1.46 by $0.35. The company had revenue of $98.92 billion for the quarter, compared to the consensus estimate of $94.87 billion. CVS Health had a return on equity of 10.51% and a net margin of 1.17%.CVS Health’s quarterly revenue was up 8.4% compared to the same quarter last year. During the same period in the previous year, the business earned $1.83 earnings per share. CVS Health has set its FY 2025 guidance at 6.300-6.400 EPS. Analysts anticipate that CVS Health Corporation will post 5.89 EPS for the current fiscal year.

CVS Health Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Shareholders of record on Thursday, October 23rd will be given a dividend of $0.665 per share. This represents a $2.66 dividend on an annualized basis and a yield of 3.4%. The ex-dividend date is Thursday, October 23rd. CVS Health’s payout ratio is presently 74.30%.

Analyst Upgrades and Downgrades

Several research analysts recently commented on CVS shares. Jefferies Financial Group increased their price objective on CVS Health from $74.00 to $80.00 and gave the company a “buy” rating in a research note on Monday, June 30th. Wolfe Research raised their price objective on CVS Health from $80.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Cantor Fitzgerald reiterated an “overweight” rating and set a $78.00 price target on shares of CVS Health in a research note on Tuesday, August 26th. Cowen reiterated a “buy” rating on shares of CVS Health in a research note on Monday, August 4th. Finally, Sanford C. Bernstein lifted their price objective on CVS Health from $72.00 to $77.00 and gave the company a “market perform” rating in a research note on Friday, September 5th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat.com, CVS Health has a consensus rating of “Moderate Buy” and an average price target of $79.80.

Insider Buying and Selling

In other CVS Health news, Director Anne A. Finucane sold 7,500 shares of the business’s stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $71.02, for a total transaction of $532,650.00. Following the sale, the director directly owned 22,156 shares in the company, valued at approximately $1,573,519.12. The trade was a 25.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 1.22% of the company’s stock.

CVS Health Company Profile

CVS Health Corporation provides health solutions in the United States. It operates through Health Care Benefits, Health Services, and Pharmacy & Consumer Wellness segments. The Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services.